http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
주요 외국의 희귀의약품과 항암제 별도 기금 제도 고찰 및 시사점
정승연(Seungyeon Jung),김수진(Sujin Kim),김동숙(Dong-Sook Kim) 대한약학회 2017 약학회지 Vol.61 No.2
The purpose of this study was to review foreign orphan or anticancer funding programs and to suggest an applicable policy development plan in the Korean domestic situation. We conducted web searches and literature review on pharmaceutical funding programs in several countries including Australia, Belgium, Canada, Italy, New Zealand, and the United Kingdom. Funding programs were studied in terms of managing agents, target medicines, beneficiaries, and sources of funding. We found out that most programs are financially dependent on their own countries and there are more programs for orphan drugs than for anticancer drugs across countries. Based on the review of foreign funding programs, we suggest that developing practical pharmaceutical funding programs may help patients to access anticancer and orphan drugs.
희귀질환 약제, 항암제 별도 기금 도입에 대한 약제급여 결정 전문가와 이해관계자 시각
김수진,정승연,김동숙,Kim, Sujin,Jung, Seungyeon,Kim, Dong-Sook 한국임상약학회 2020 한국임상약학회지 Vol.30 No.3
Background & objective: The Korean government has expanded its benefit coverage to enhance patients' access to orphan drugs and cancer medicines. However, the number of new drugs whose indications were not applied to reimbursement in health insurance was increased. This study aimed to understand the perspectives of experts and various stakeholders on the introduction of a new funding program for cancer treatment and orphan drugs. Methods: We conducted email surveys comprising 19 questions, from September 9 to 26, 2016. We distributed questionnaires to members of the Pharmaceutical Benefit Appraisal Committee and Cancer Assessment Committee. We also conducted a qualitative study through group interviews with stakeholders, including pharmaceutical companies and some patient groups for diseases. Results: A total of 35 survey respondents recommended the introduction of a funding program for orphan drugs, whereas 66% recommended the launch of funding for anticancer drugs. In addition, most pharmaceutical companies and patient groups recommended the introduction of new funding programs targeting patients with cancer and rare diseases. However, some participants asserted that it would be more appropriate to modify the existing reimbursement scheme than launch new funding. Conclusion: This study concluded that introducing new funding needs a social consensus to relieve financial hardships at the patient level.